Verapamil can be combined with other antihypertensives, but dose adjustments may be necessary to avoid excessive blood-pressure lowering. Your prescriber will determine the safest combination based on your overall regimen.
Peripheral edema is a common side effect. Elevating the legs and reducing sodium intake may help, but report the swelling to your clinician; a dose change or alternative therapy might be required.
NSAIDs (e.g., ibuprofen) can reduce verapamil’s blood-pressure effect, while certain antihistamines may increase heart-rate slowing. Check with a pharmacist before adding any new OTC product.
Patients often notice relief from chest pain within a few days, but full therapeutic benefit may take up to two weeks as the dosage is titrated.
Verapamil does not have a direct effect on lipid metabolism; it neither raises nor lowers cholesterol.
Yes, but keep the medication in its original labelled container, carry a copy of the prescription, and be aware of any country-specific import restrictions for prescription drugs.
Both strengths contain the same active ingredient; the higher-dose tablet simply delivers more drug per tablet, allowing for fewer pills per day when higher dosing is needed.
UK-marketed immediate-release verapamil tablets commonly bear the imprint “V 40” for the 40 mg strength and “V 120” for the 120 mg strength, followed by the manufacturer’s logo. Verify against the packaging.
Consistent timing helps maintain stable blood levels and improves blood-pressure control. Aim to take each dose at roughly the same intervals every day.
Yes, orthostatic hypotension can occur, especially after the first few doses. Rise slowly from sitting or lying positions and report persistent dizziness to your doctor.
Verapamil is a calcium-channel blocker used to manage several heart-related conditions. This article covers verapamil, available as a generic medication and marketed under brand names such as Isoptin and Calan. It is supplied as a pill in strengths of 40 mg and 120 mg and is prescribed in the United Kingdom under the oversight of the Medicines and Healthcare products Regulatory Agency (MHRA).
Verapamil belongs to the dihydropyridine-non-dihydropyridine class of calcium-channel blockers. It binds to L-type calcium channels on cardiac and vascular smooth-muscle cells, reducing calcium influx. This leads to:
The onset of action after oral ingestion is typically within 30-60 minutes, with peak plasma concentrations reached in about 2 hours. The drug’s effects last 4-6 hours for the immediate-release tablets, which is why dosing is usually divided throughout the day.
Verapamil is approved by the MHRA for the following indications:
These uses are based on clinical trial data and are reflected in the product’s summary of characteristics (SmPC) issued in the UK.
If any of these serious reactions occur, seek urgent medical attention.
Patients should disclose all prescription medicines, over-the-counter products, and herbal supplements to their prescriber.
Hypertension:
Start with 80 mg (two 40 mg tablets) taken twice daily.
Dose may be increased to 120 mg taken two to three times daily based on response and tolerability.
Chronic Angina:
Typical regimen is 120 mg taken three times daily.
Supraventricular Tachycardia:
80 mg taken three times daily is common; adjust according to heart-rate control.
Maximum daily dose should not exceed 480 mg for immediate-release tablets unless directed by a specialist.
If you miss a dose and it is less than 6 hours until the next scheduled dose, take the missed tablet as soon as you remember. Skip the missed dose if it is close to the next dose; do not double-dose.
Signs of overdose may include severe hypotension, bradycardia, and cardiac conduction disturbances. Seek emergency care immediately; treatment focuses on supportive measures such as intravenous fluids and, if necessary, atropine for bradycardia.
Do not stop verapamil abruptly, especially if used for arrhythmia control. Gradual tapering under medical supervision reduces the risk of rebound tachycardia or hypertension.
Regular follow-up enables dose adjustments and early detection of adverse effects.
This article provides educational information about verapamil and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
